| To: | Glaxo Group Limited (trademarks@gsk.com) |
| Subject: | TRADEMARK APPLICATION NO. 88381582 - NAMVONA - 82774078 |
| Sent: | 1/31/2020 12:30:36 PM |
| Sent As: | ECOMPET |
| Attachments: |
United States Patent and Trademark Office (USPTO)
|
U.S. Application Serial No. 88381582
Mark: NAMVONA
|
|
|
Correspondence Address: Merilee J. Arevalo GSK LBP, 5.5A 5 MOORE DRIVE RESEARCH TRIANGLE PARK NC 27709-3398 |
|
|
Owner: Glaxo Group Limited
|
|
|
Reference/Docket No. 82774078
Correspondence Email Address: trademarks@gsk.com |
|
Issue date: January 31, 2020
The petition to the Director in the trademark application above is GRANTED. See 37 C.F.R. §2.146(a)(3).
The application will be returned to the assigned trademark examining attorney to consider petitioner’s request to amend the basis from Section 1(b) to Section 44(e) of the Trademark Act. If the examining attorney accepts the amendment, the application will be republished. If the examining attorney refuses it, applicant will be notified of the refusal.
Since you have requested to substitute the Section 44(e) basis, the notice of allowance will be cancelled and the Section 1(b) basis will be deleted. The application will then be forwarded to the examining attorney to examine the amendment to substitute Section 44(e) as the basis for registration. The Section 1(b) basis cannot be reinserted. See TMEP §806.03(j). If the amendment is accepted the application will be republished. 37 C.F.R. §2.35(b)(2). If the amendment is refused, applicant will be notified of the refusal.
Please contact the assigned examining attorney directly to check on the status of the amendment to the basis.
/Deborah D Mays/
Paralegal Specialist
Office of the Deputy Commissioner
for Trademark Examination Policy
(571) 272 9575